OncoMatch/Clinical Trials/NCT06268210
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
Is NCT06268210 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Lazertinib+Pemetrexed+Carboplatin and Lazertinib for non-small cell lung cancer.
Treatment: Lazertinib+Pemetrexed+Carboplatin · Lazertinib — In the randomized, multicenter Phase II clinical trial, we aim to evaluate the efficacy and safety of Lazertinib monotherapy or the combination of Lazertinib and cytotoxic chemotherapy as neoadjuvant therapy in patients with resectable, treatment-naive EGFR-mutant (exon 19 deletion or exon 21 L858R) non-small cell lung cancer, ranging from clinical stage IB to IIIB. The study is designed to assess the impact on pathological response, as well as effectiveness and safety considerations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
Required: EGFR l858r mutation
Disease stage
Required: Stage IB, IIA, IIB, IIIA, IIIB (AJCC 8th edition)
Excluded: Stage IIIC, IV
AJCC 8th edition, stages IB-IIIB; evidence of locally advanced and/or metastatic disease (Stage IIIC-IV) [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
Hemoglobin: ≥9.0 g/dL; Absolute neutrophil count: ≥1.5 × 10^9/L; Platelet count: ≥100 × 10^9/L
Kidney function
Creatinine clearance: ≥50 ml/min or serum creatinine ≤1.5 × ULN
Liver function
Serum bilirubin: ≤1.5 x upper limit of normal (ULN); ALT and AST: ≤2.5 x ULN
Cardiac function
QTcF > 470 msec based on three ECGs; significant abnormalities in rhythm, conduction, or morphology at rest on ECG; clinically significant heart failure, congenital long QT syndrome, known concomitant drug administration that prolongs the QT interval, or any factors that increase the risk of QTc prolongation or arrhythmias
Adequate and normal organ and bone marrow function, defined as follows: Hemoglobin: ≥9.0 g/dL Absolute neutrophil count: ≥1.5 × 10^9/L Platelet count: ≥100 × 10^9/L Serum bilirubin: ≤1.5 x upper limit of normal (ULN) ALT and AST: ≤2.5 x ULN Creatinine clearance: ≥50 ml/min or serum creatinine ≤1.5 × ULN; cardiac criteria: QTcF > 470 msec, significant ECG abnormalities, heart failure, long QT syndrome, drugs that prolong QT, family history of QTc prolongation or sudden death under 40
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06268210 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require EGFR?
Yes, EGFR exon 19 deletion is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR l858r mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage IB or IIA or IIB or IIIA or IIIB is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages